Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 23

1.

The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.

Kurmasheva RT, Dudkin L, Billups C, Debelenko LV, Morton CL, Houghton PJ.

Cancer Res. 2009 Oct 1;69(19):7662-71. doi: 10.1158/0008-5472.CAN-09-1693. Epub 2009 Sep 29.

PMID:
19789339
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies.

Coiffier B, Ribrag V.

Leuk Lymphoma. 2009 Dec;50(12):1916-30. doi: 10.3109/10428190903207548. Review.

PMID:
19757306
[PubMed - indexed for MEDLINE]
3.

Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, Pritchard K, Eisen A, Vandenberg T, Taylor M, Sauerbrei E, Mishaeli M, Huntsman D, Walsh W, Olivo M, McIntosh L, Seymour L.

J Clin Oncol. 2009 Sep 20;27(27):4536-41. doi: 10.1200/JCO.2008.21.3033. Epub 2009 Aug 17.

PMID:
19687332
[PubMed - indexed for MEDLINE]
Free Article
4.

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.

Soria JC, Shepherd FA, Douillard JY, Wolf J, Giaccone G, Crino L, Cappuzzo F, Sharma S, Gross SH, Dimitrijevic S, Di Scala L, Gardner H, Nogova L, Papadimitrakopoulou V.

Ann Oncol. 2009 Oct;20(10):1674-81. doi: 10.1093/annonc/mdp060. Epub 2009 Jun 23.

PMID:
19549709
[PubMed - indexed for MEDLINE]
Free Article
5.

Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition.

Breuleux M, Klopfenstein M, Stephan C, Doughty CA, Barys L, Maira SM, Kwiatkowski D, Lane HA.

Mol Cancer Ther. 2009 Apr;8(4):742-53. doi: 10.1158/1535-7163.MCT-08-0668.

PMID:
19372546
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.

Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T.

Clin Cancer Res. 2009 Mar 1;15(5):1612-22. doi: 10.1158/1078-0432.CCR-08-2057. Epub 2009 Feb 17.

PMID:
19223496
[PubMed - indexed for MEDLINE]
Free Article
7.

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Gr├╝nwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A; RECORD-1 Study Group.

Lancet. 2008 Aug 9;372(9637):449-56. doi: 10.1016/S0140-6736(08)61039-9. Epub 2008 Jul 22.

PMID:
18653228
[PubMed - indexed for MEDLINE]
8.

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.

O'Donnell A, Faivre S, Burris HA 3rd, Rea D, Papadimitrakopoulou V, Shand N, Lane HA, Hazell K, Zoellner U, Kovarik JM, Brock C, Jones S, Raymond E, Judson I.

J Clin Oncol. 2008 Apr 1;26(10):1588-95. doi: 10.1200/JCO.2007.14.0988. Epub 2008 Mar 10.

PMID:
18332470
[PubMed - indexed for MEDLINE]
Free Article
9.

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Ramon y Cajal S, Jones S, Vidal L, Shand N, Macarulla T, Ramos FJ, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane HA, Lebwohl D, Baselga J.

J Clin Oncol. 2008 Apr 1;26(10):1603-10. doi: 10.1200/JCO.2007.14.5482. Epub 2008 Mar 10. Erratum in: J Clin Oncol. 2010 Dec 20;28(36):5350.

PMID:
18332469
[PubMed - indexed for MEDLINE]
Free Article
10.

Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling.

DeYoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW.

Genes Dev. 2008 Jan 15;22(2):239-51. doi: 10.1101/gad.1617608.

PMID:
18198340
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

IRS-1: auditing the effectiveness of mTOR inhibitors.

Easton JB, Kurmasheva RT, Houghton PJ.

Cancer Cell. 2006 Mar;9(3):153-5. Review.

PMID:
16530700
[PubMed - indexed for MEDLINE]
Free Article
12.

TOR signaling in growth and metabolism.

Wullschleger S, Loewith R, Hall MN.

Cell. 2006 Feb 10;124(3):471-84. Review.

PMID:
16469695
[PubMed - indexed for MEDLINE]
Free Article
13.

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.

O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N.

Cancer Res. 2006 Feb 1;66(3):1500-8.

PMID:
16452206
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Growing roles for the mTOR pathway.

Sarbassov DD, Ali SM, Sabatini DM.

Curr Opin Cell Biol. 2005 Dec;17(6):596-603. Epub 2005 Oct 13. Review.

PMID:
16226444
[PubMed - indexed for MEDLINE]
15.

The coordinate regulation of the p53 and mTOR pathways in cells.

Feng Z, Zhang H, Levine AJ, Jin S.

Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8204-9. Epub 2005 May 31.

PMID:
15928081
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Regulation of cap-dependent translation by eIF4E inhibitory proteins.

Richter JD, Sonenberg N.

Nature. 2005 Feb 3;433(7025):477-80. Review.

PMID:
15690031
[PubMed - indexed for MEDLINE]
17.

Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex.

Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, Witters LA, Ellisen LW, Kaelin WG Jr.

Genes Dev. 2004 Dec 1;18(23):2893-904. Epub 2004 Nov 15.

PMID:
15545625
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

The LKB1 tumor suppressor negatively regulates mTOR signaling.

Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, DePinho RA, Cantley LC.

Cancer Cell. 2004 Jul;6(1):91-9.

PMID:
15261145
[PubMed - indexed for MEDLINE]
19.

Lost in translation: dysregulation of cap-dependent translation and cancer.

Bjornsti MA, Houghton PJ.

Cancer Cell. 2004 Jun;5(6):519-23. Review.

PMID:
15193254
[PubMed - indexed for MEDLINE]
20.

Akt and hypoxia-inducible factor-1 independently enhance tumor growth and angiogenesis.

Arsham AM, Plas DR, Thompson CB, Simon MC.

Cancer Res. 2004 May 15;64(10):3500-7.

PMID:
15150104
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk